Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

ClinicalTrials.gov ID: NCT00030472

Public ClinicalTrials.gov record NCT00030472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix

Study identification

NCT ID
NCT00030472
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gynecologic Oncology Group
Network
Enrollment
Not listed

Conditions and interventions

Interventions

  • pegylated liposomal doxorubicin hydrochloride Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2001
Primary completion
Sep 30, 2006
Completion
Not listed
Last update posted
Apr 10, 2013

Started 2001

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Jonsson Comprehensive Cancer Center, UCLA Los Angeles California 90095-1740
Community Hospital of Los Gatos Los Gatos California 95032
MBCCOP - Hawaii Honolulu Hawaii 96813
Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa 52242-1009
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda Maryland 20892-1182
Tufts - New England Medical Center Boston Massachusetts 02111
Cooper University Hospital Camden New Jersey 08103-1489
Roswell Park Cancer Institute Buffalo New York 14263-0001
State University of New York Health Sciences Center - Stony Brook Stony Brook New York 11794-8091
Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina 27599-7295
Charles M. Barrett Cancer Center at University Hospital Cincinnati Ohio 45267-0526
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195
Abington Memorial Hospital Abington Pennsylvania 19001-3788
University of Texas Medical Branch Galveston Texas 77555-0587
University of Texas M.D. Anderson CCOP Research Base Houston Texas 77030-4009
Fletcher Allen Health Care - Medical Center Campus Burlington Vermont 05401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00030472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 10, 2013 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00030472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →